Study of CAD-9303 in Subjects With Schizophrenia

Summary

This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.

Timeline

Start

2020-02-28

Primary completion

2021-09-22

Completion

2021-11-24

Drugs

Indications